Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the safety, tolerability and objective response rate of SKB264 as combination with therapy in subjects with advanced or metastatic non-small cell lung cancer.
Full description
This is a multicenter, open-label study of SKB264 as combination therapy in subjects with NSCLC. Approximately up to 296 subjects will be enrolled in this study including around 36 (may expand) subjects for safety run-in period and 200 subjects for expansion period.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Exclusion Criteria
Primary purpose
Allocation
Interventional model
Masking
278 participants in 7 patient groups
Loading...
Central trial contact
Xiaoping Jin, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal